GlassScriptPhysician profile
Nour B Salus
NPI 1417634544
$2,254.92
in general payments reported to CMS, 2019-2025
10 companies · $750 in 2025
The $750 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $160 · 2024: $1,344 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,235 · Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,234.89 |
| Food and Beverage | $1,020.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,325.45 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Inspire Medical Systems, INC. | $605.54 | 2025 | Inspire |
| Genzyme Corporation | $87.68 | 2025 | |
| Amgen INC. | $86.96 | 2023-2025 | Repatha, Tezspire |
| Aerin Medical INC. | $39.51 | 2025 | |
| Merck Sharp & Dohme LLC | $26.19 | 2023 | Verquvo |
| Daiichi Sankyo INC. | $24.36 | 2024 | Injectafer |
| Atricure, INC. | $21.07 | 2023 | |
| Hikma Pharmaceuticals USA | $20.45 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $17.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nour Salus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.